Limits...
Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.

Keaveny TM, McClung MR, Genant HK, Zanchetta JR, Kendler D, Brown JP, Goemaere S, Recknor C, Brandi ML, Eastell R, Kopperdahl DL, Engelke K, Fuerst T, Radcliffe HS, Libanati C - J. Bone Miner. Res. (2014)

Bottom Line: We found that, compared with baseline, the finite element estimates of hip strength increased from 12 months (5.3%; p < 0.0001) and through 36 months (8.6%; p < 0.0001) in the denosumab group.For the placebo group, hip strength did not change at 12 months and decreased at 36 months (-5.6%; p < 0.0001).In conclusion, treatment with denosumab increased hip and spine strength as estimated by FEA of QCT scans compared with both baseline and placebo owing to positive treatment effects in both the trabecular and cortical bone compartments.

View Article: PubMed Central - PubMed

Affiliation: University of California Berkeley, Berkeley, CA, USA; O.N. Diagnostics, Berkeley, CA, USA.

Show MeSH

Related in: MedlinePlus

Relationship between changes from baseline in hip and spine strength (in Newtons), as estimated by the finite element analysis (FEA), in denosumab (closed circles) and placebo (open circles) subjects.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4238810&req=5

fig04: Relationship between changes from baseline in hip and spine strength (in Newtons), as estimated by the finite element analysis (FEA), in denosumab (closed circles) and placebo (open circles) subjects.

Mentions: For individual subjects at 36 months, changes in hip strength were significantly, but weakly, correlated with changes in spine strength for the denosumab group (r = 0.38; p = 0.02) but not for the placebo group (r = 0.18; p = 0.39) (Fig. 4). At 36 months, spine strength increased in all denosumab-treated subjects and hip strength increased in all but two subjects, whereas both the hip and spine strength decreased for the majority of placebo-treated subjects.


Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.

Keaveny TM, McClung MR, Genant HK, Zanchetta JR, Kendler D, Brown JP, Goemaere S, Recknor C, Brandi ML, Eastell R, Kopperdahl DL, Engelke K, Fuerst T, Radcliffe HS, Libanati C - J. Bone Miner. Res. (2014)

Relationship between changes from baseline in hip and spine strength (in Newtons), as estimated by the finite element analysis (FEA), in denosumab (closed circles) and placebo (open circles) subjects.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4238810&req=5

fig04: Relationship between changes from baseline in hip and spine strength (in Newtons), as estimated by the finite element analysis (FEA), in denosumab (closed circles) and placebo (open circles) subjects.
Mentions: For individual subjects at 36 months, changes in hip strength were significantly, but weakly, correlated with changes in spine strength for the denosumab group (r = 0.38; p = 0.02) but not for the placebo group (r = 0.18; p = 0.39) (Fig. 4). At 36 months, spine strength increased in all denosumab-treated subjects and hip strength increased in all but two subjects, whereas both the hip and spine strength decreased for the majority of placebo-treated subjects.

Bottom Line: We found that, compared with baseline, the finite element estimates of hip strength increased from 12 months (5.3%; p < 0.0001) and through 36 months (8.6%; p < 0.0001) in the denosumab group.For the placebo group, hip strength did not change at 12 months and decreased at 36 months (-5.6%; p < 0.0001).In conclusion, treatment with denosumab increased hip and spine strength as estimated by FEA of QCT scans compared with both baseline and placebo owing to positive treatment effects in both the trabecular and cortical bone compartments.

View Article: PubMed Central - PubMed

Affiliation: University of California Berkeley, Berkeley, CA, USA; O.N. Diagnostics, Berkeley, CA, USA.

Show MeSH
Related in: MedlinePlus